Among patients with the shorter PFS, we detected variants in genes that have been already associated with resistance to anti-EGFR MoAbs in CRC, such as KRAS, MAP2K1, and FBXW7, as well as in the new candidate gene NF1. We must acknowledge that the lack of a control arm prevents from the possibility to define whether these variants are predictive or prognostic. Here, MAP2K1 is linked to colorectal carcinoma.